Table 1.
Sociodemographics and clinical characteristics
| Variant of concern | N = (%) | Age (years) median (range) | Male | Hospital admission | Sequence confirmed | Time since symptom onset (days) median (range) |
|---|---|---|---|---|---|---|
| D614G | 20 (30%) | 53 (22–74) | 9 (45%) | 9 (45%) | 0 (0%) | 38 (30–45) |
| Alpha | 11 (17%) | 48 (25–76) | 6 (55%) | 9 (82%) | 11 (100%) | 39 (24–58) |
| Alpha + E484K | 2/11 | 62 (48–76) | 0 | 2/2 | 2/2 | 41 (24–58) |
| Beta | 8 (12%) | 41 (18–53) | 3 (38%) | 0 | 7 (88%) | 39 (30–63) |
| Gamma | 4 (6%) | 35 (27–10) | 2 (50%) | 0 | 4 (100%) | 40 (38–55) |
| Delta | 11 (17%) | 31 (19–63) | 6 (55%) | 1 (9%) | 10 (91%) | 46 (36–52) |
| Omicron BA.1 | 8 (12%) | 31 (21–45) | 4 (50%) | 0 | 3 (38%) | 44 (25–75) |
| Omicron BA.2 | 4 (6%) | 51 (31–55) | 4 (100%) | 0 | 4 (100%) | 40 (39–41) |
| Total | 66 | 41 (18–76) | 34 (52%) | 21 (32%) | 39 (59%) | 40 (24–75) |
A summary of the convalescent SARS-CoV-2 patients included in this study. See also Table S1 for a more comprehensive overview per individual.